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Introduction
Microglia are the resident immune cells of  the CNS and are part of  the innate immune system (1). During 
inflammation, microglia recruit lymphocytes and peripheral monocytes. These cells also produce inflamma-
tory cytokines, proteases, and free radicals, which all contribute to CNS damage. (1) Conversely, microglia 
also maintain CNS integrity by removing apoptotic cells, providing trophic support, and potentially enhanc-
ing remyelination (2). In patients with multiple sclerosis (MS), distinct subsets of  microglia have been sug-
gested to play both beneficial and destructive roles (2–4). The heterogeneity of  microglial phenotypes at 
different time points and in different CNS regions further diversify their roles (5, 6). Thus, animal studies 
that model human MS pathology are warranted to investigate the association of  microglial activation with 
damage and to explore microglial phenotypes in distinct disease stages.
Myelin oligodendrocyte glycoprotein–induced (MOG35–55–induced) experimental autoimmune enceph-
alomyelitis (EAE) is a widely studied animal model of  MS (7). In mice, MOG35–55 EAE induces a myelin tar-
geted adaptive immune-led response with a chronic, nonremitting phenotype characterized by an ascending 
myelitis and optic neuritis. EAE lesions demonstrate perivenous inflammatory mononuclear infiltrate with 
gliosis, confluent plaques of  demyelination, and relative axonal sparing (8). Up to 90% of  EAE mice develop 
retinal and optic nerve lesions, making the afferent visual system an important location in which to study 
microglial changes in neuroinflammation (3, 8, 9).
It has been suggested that microglial activation fuels inflammation and recruits additional immune cells 
from the periphery (3). However, whether microglial activation also plays a direct role in retinal neurodegen-
eration or neuronal repair has remained unclear (8). For CNS white matter, it was recently suggested that a 
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switch from a proinflammatory to a proregenerative microglial phenotype coincides with the initiation of  
remyelination and repair (10, 11); however, their role in unmyelinated retina and gray matter is still undeter-
mined (2, 8). These reports of  dynamic microglial changes have further been challenged by data suggesting 
(a) a stable number of  retinal microglia over the course of  EAE or (b) no effect of  microglial depletion on the 
severity of  EAE (12, 13). As a consequence, the true dynamics of  microglia remain uncertain.
Prior animal studies performing cross-sectional histopathological analyses at specific time points are 
united by the limited access to relevant tissue, leading to conflicting results due to different time points and 
pseudolongitudinal analyses. Therefore, noninvasive techniques, which can longitudinally monitor neu-
roinflammation with close-to-cellular resolution, can add to our understanding. The retina is an accessible 
part of  the CNS for in vivo imaging and enables the noninvasive investigation of  dynamic processes with 
high-resolution, nontoxic, light-based methods such as optical coherence tomography (OCT) and confocal 
scanning laser ophthalmoscopy (CSLO). In CX3CR1GFP/+–knock-in mice, microglia, macrophages, mono-
cytes, DCs, and NK cells express green fluorescent protein (GFP), which can be imaged through CSLO 
(14), without immunologic alterations (15). The combined use of  longitudinal retinal OCT and CSLO in 
EAE of  CX3CR1GFP/+–knock-in mice allows for the dynamic study of  innate immune activation in the 
retina and, thereby, allows for more direct and longitudinal assessment of  innate immune cell response 
compared with traditional histopathology.
We aimed to longitudinally characterize the association of  microglial activation with disease severity 
and neuroaxonal damage, as well as to identify the transcriptomic signature of  retinal innate immune cells 
at distinct time points in EAE.
Results
Despite microglia being the most motile retinal innate immune cells, their activation in the retina has been 
only partially described in EAE; the number of  resident microglia increases early (around 7 days postin-
fection [dpi]) (8). Microglia then spread out, become activated, and proliferate quickly, reaching their peak 
count around 11–15 dpi. Their number remains elevated until 60 dpi (8, 9, 13, 16). Whether microglial 
activation plays a direct injurious or protective role in retinal neuroinflammation and how these processes 
are related in time has remained unclear (8). As a consequence, we first investigated the true dynamics of  
retinal innate immune cells in EAE.
Two distinct waves of  retinal innate immune cell activation in EAE. After immunization with MOG35–55 pep-
tide in complete Freund’s adjuvant containing mycobacterium tuberculosis and with 200 ng pertussis toxin, 
7 EAE mice developed neurological symptoms (onset: [median (min–max)]: 11 dpi [8–15 dpi]) and were 
followed for 56 days after induction (Supplemental Figure 1A; supplemental material available online with 
this article; https://doi.org/10.1172/jci.insight.149228DS1).
During the inner retinal layer (IRL) swelling preonset (Figure 1C), the CX3CR1 GFP+ cell density (0 
dpi: 15.4 ± 3.3 cells per selected area; 13 dpi: 17.6 ± 3.7 cells) and soma area (0 dpi: 212.2 ± 52.7 pixel [px]; 
13 dpi: 254.0 ± 67.1 px) measured by CSLO increased only slightly, without reaching significance. However, 
cell density increased (31 dpi: 30.0 ± 4.2, P < 0.001) and soma area decreased (31 dpi: 144.4 ± 49.2 P < 
0.001) significantly in the acute inflammatory and neurodegenerative phase thereafter (13–31 dpi, Figure 1, 
A–C). Conversely, the density of  CX3CR1 GFP+ cells decreased (56 dpi: 24.4 ± 6.0, P = 0.003) and the soma 
area increased (56 dpi: 184.7 ± 45.8, P < 0.001) again in the chronic phase (31–56 dpi) with stabilized neuro-
nal content. Next, we investigated if  neuroaxonal loss was associated with early innate immune activation.
Early innate immune activation predicts ultimate neuronal cell loss. At 56 dpi, the retinal ganglion cell (RGC) 
count measured by the average Brn3a+ cell count was 434.5 ± 117.8 per retinal field. Eyes with severe RGC loss 
(RGC count/field ≤ median of 460.2) showed a higher peak of CX3CR1 GFP+ cell density 25 dpi (β = 10.0, 
standard error [SE] = 3.5, P = 0.020) and 38 dpi (β = 10.6, SE = 3.8, P = 0.016) compared with eyes with mild 
RGC loss (RGC count > median; Figure 1, D–F). Eyes with mild RGC loss had significantly smaller CX3CR1 
GFP+ cells around the peak of retinal inflammation (38 dpi) compared with eyes with severe RGC loss (β = 
–123.0, SE = 20.0, P < 0.001). This suggests that the magnitude and cellular composition of the inflammatory 
response impacts neuronal survival but is not sufficient to explain the pronounced differences observed. The 
observation of 2 distinct peaks separated by a trough identified for us 2 separate waves (~15 dpi and ~40 dpi) 
of  innate immune cell activation. We therefore hypothesized that different innate immune cell populations 
with distinct expression profiles contribute to the so far unexplained observed differences, and we embarked to 
characterize the transcriptional profile of innate immune cells during the course of EAE.
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Transcriptional profiling during EAE is most variable in microglia. To characterize retinal innate immune 
cells, we implemented a second EAE experiment. We performed single-cell RNA sequencing (scRNA-seq) 
of  retinal CD11b+ cells obtained at 0 (not immunized), 6 (preonset), and 25 dpi (peak of  retinal inflamma-
tion). Mice at 0 and 6 dpi were free of  clinical signs. For 25 dpi, 13 of  20 EAE mice developed neurological 
signs (Supplemental Figure 1B).
A total of  280 CD11b+ retinal cells were sorted: at day 0 (i.e., nonimmunized controls, n = 121 cells), 
at day 6 (n = 118 cells), and at day 25 (n = 41 cells) after immunization. Sorted cells were then clustered 
according to their transcriptomic profile, and different cell subsets were identified (Figure 2 and Table 1). 
The full data set and raw data are accessible on Gene Expression Omnibus (GEO; GSE173378; https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE173378). We identified microglia, macrophages, NK 
cells, and activated monocytes by expression of  specific molecular markers (Table 1). The different CD11b+ 
cell type fractions changed only marginally over the course of  EAE, with a slight, transitory increase of  
macrophages prior to EAE onset (6 dpi, n.s.). Whereas macrophages, NK cells, and monocytes showed a 
rather homogenous expression profile, microglial profiles were more heterogenous, especially over to course 
of  EAE — suggesting an innate immune cell shift mainly in the microglial compartment.
Transcriptional profiling reveals a switch of  microglial phenotype from injurious to protective between peak of  disease 
and the later chronic condition. Prior studies have not clarified the role of  early microglia in EAE. One study 
Figure 1. Longitudinal in vivo imaging in EAE. (A and B) Preonset (light gray 0–13 dpi), the cell density (A) and soma area (B) of CX3CR1 GFP+ cells increase. 
Whereas the cell density of CX3CR1 GFP+ cells further increases during the acute phase (13–30 dpi; medium gray) and decreases in the chronic phase (31–56 
dpi; dark gray), the soma area of CX3CR1 GFP+ cells decreases in the acute phase and then peaks again the chronic phase. (C) The IRL thickness increases 
before onset, drops dramatically during the acute phase, and stabilizes in the chronic phase of EAE. (D and E) Eyes with severe RGC loss compared with 
eyes with mild RGC loss at 56 dpi showed a higher cell density of CX3CR1 GFP+ cells 25 dpi and 38 dpi (D) and a less relevant drop of CX3CR1 GFP+ cell soma 
area (E). (F) Cell density and soma area changes of CX3CR1 GFP+ cells are qualitatively visible by CSLO (please note: images falsely colorized). For A–E, data 
are shown as mean ± SEM; experiment included eyes of 7 mice.
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Figure 2. Transcriptomic profile of retinal CD11b+ cells during the course of EAE. (A) Heatmap of transcriptomic 
profile in different CD11b+ cell types. (B) t-SNE plot of CD11b+ immune cell clusters based on genetic markers from A 
(pooled from 0, 6, and 25 dpi).
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suggested that depletion of  microglia before induction of  EAE was associated with worse clinical disease 
but, paradoxically, no greater injury — while another study suggested a beneficial effect of  microglial deple-
tion shortly after EAE induction (12, 17). These seemly conflicting findings necessitate further characteriza-
tion of  innate immune response in the retina with EAE. We theorized that an important way to distinguish 
the different subpopulations could be an assessment of  their transcriptional profiles.
We therefore characterized the expression profiles of microglia at 6 dpi (before onset; total cell count, n = 
66) and 25 dpi (peak of retinal inflammation; total cell count, n = 28) compared with 0 dpi (total cell count, n = 
80), and we generated interaction networks and enrichment analyses using STRING and STRING ENRICH-
MENT by Cytoscape (Figure 3 and refs. 18, 19). When performing pathway enrichment analyses in transcripts, 
which were at least 2-fold upregulated, our data show an enrichment of inflammatory microglial pathways at 
6 dpi, such as neutrophil granulation and reactive oxygen species (ROS) production, as well as CLEC7A (Dec-
tin-1) signaling, a pathway inducing the production of various proinflammatory cytokines and chemokines, 
including TNF-α and IL-1β, and triggering phagocytosis and further ROS production (Table 2 and refs. 20, 21). 
At 25 dpi, these pathways were not further enriched; in contrast, we found an enrichment of antiinflammatory 
pathways such as the biosynthesis of resolvins, which are necessary for the metabolism and degradation of  
ROS (22). The switch to a noninflammatory, protective role of microglia at 25 dpi was further supported by the 
downregulation of inflammatory pathways such as antigen-processing cross-presentation and microglial polar-
ization pathways (β-catenin–independent WNT signaling, planar cell polarity/convergent extension [PCP/
CE] pathway), which are characteristic for proinflammatory and phagocytic microglia. (23, 24).
It remains under debate whether a downregulation of  harmful or an upregulation of  protective microgli-
al pathways can, when timed correctly, achieve an attenuation of  EAE in mice — or maybe even of  human 
MS as a potential therapeutic target. So far, the most promising target in the literature, which was reported 
as elevated at 25 dpi in our EAE study, is growth arrest–specific protein 6 (GAS6). In microglia, GAS6 is 
described to improve the clearance of  apoptotic cell bodies and motility (25). However, it is also involved in 
survival of  neuronal and other glial cells, making an off-target cell effect less concerning. In EAE, the admin-
istration of  GAS6 leads to reduced demyelination and inflammation, as well as enhanced remyelination (25). 
A study in cuprizone-induced demyelination, a toxic demyelination model, confirmed the positive effects of  
GAS6, showing a better clearance of  debris, more remyelination, and maturation of  oligodendrocytes and 
a higher number of  myelinated axons (26, 27). Although the microglial expression of  GAS6 under healthy 
conditions is lower in humans than in mice, descriptive studies showed that MS patients with a higher GAS6 
concentration in the cerebrospinal fluid (CSF) underwent shorter and less severe MS flares (28). Therefore, 
the administration or pharmacological enhancement of  GAS6 — or an earlier uptake in expression — might 
reduce tissue damage and disability accrual also in MS. Another promising target described in the MS liter-
ature and enhanced at 25 dpi might be a suppressor of  cytokine signaling 3 (SOCS3), an inhibitor of  JAK/
STAT and leptin pathways in microglia, which could reduce the toxic inflammatory response during relapse 
— probably by regulating IL-6 (29, 30). However, caution is warranted, since SOCS3 also inhibits the produc-
tion of  leukemia inhibitory factor (LIF), a factor involved in survival and differentiation of  oligodendrocytes 
(31). Equal care should be taken, when considering Arachidonate 5-lipoxygenase (ALOX5) as a therapeutic 
target, which was elevated at both 6 and 25 dpi in our data set. ALOX5 seems to be involved in both the pro-
duction of  proinflammatory chemotactic factor and antiinflammatory resolvins during different stages of  
Table 1. Cell type and microglia subset fractions during the course of EAE
Molecular markers
Cell type fraction
Baseline 6 dpi 25 dpi
Microglia Tmem119, P2ry12, Il1a, Sgk1, Sparc, Rhob 0.694 0.593 0.707
NK cells Nkg7 0.041 0.025 0.049
Macrophages CD74, H2−Eb1, H2−Aa 0.231 0.263 0.195
Monocytes Plac8, Nr4a1, Ly6i, Smpdl3a, Napsa, Fcgr4, Ly6a, Msrb1, Fabp4 0.033 0.119 0.049
Cell type fraction defined as the fraction of CD11b+ cells. The subsets were clustered by transcriptomic profile (pooled 
from 0, 6, and 25 dpi). Only molecular markers reported for microglia that remained significant after correction for 
multiple testing using all features in the data set (Bonferroni-Holm) are shown.
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EAE, which explains the inconsistencies of  previous studies on ALOX5’s effects in EAE and underlines the 
importance of  exactly timed therapies when targeting microglia during the disease course (32–34).
Discussion
The importance of  the innate immune cells in the pathological processes that unfold in response to inflam-
matory demyelinating injury to the CNS is unambiguous. Both microglia and infiltrating innate immune 
cells (i.e., monocytes, macrophages, and neurophils) play a role in disease processes, and they likely partici-
pate in injury as well as protection (2, 10, 35, 36). The role of  microglia and other innate immune cells is bet-
ter understood in the white matter — the primary site of  adaptive immune infiltration and injury. However, 
damage to the gray matter is critical in mediating permanent irrecoverable injury in MS and EAE (37, 38). 
Therefore, it is crucial to understand the dynamics of  the retinal innate immune response and determining 
whether innate immune cells play their roles for mediating and protecting against injury simultaneously or 
at different times — even via separate populations of  cells.
Figure 3. Interaction network of transcripts showing changed expression at 6 dpi (center) or 25 dpi (rim) compared with baseline. Node color mapped 
continuously dependent on logFC from blue for reduced expression (6 dpi, logFC –1.92; 25 dpi, logFC –2.78) to red for enhanced expression (6 dpi, logFC 1.92; 
25 dpi, logFC 2.78); black signifies absence of significant change at respective time point. Edge widths mapped continuously by interaction score from 0.4 
(minimal width) to 1 (maximal width).
7
T E C H N I C A L  A D V A N C E
JCI Insight 2021;6(11):e149228  https://doi.org/10.1172/jci.insight.149228
Table 2. Enriched pathway for ≥ 2-fold enhanced and reduced transcripts at 6 dpi and 25 dpi in EAE compared with baseline
Description Background genes Genes FDR value Genes P value
Enriched pathways for ≥ 2-fold enhanced expression at 6 dpi versus baseline
Innate immune system 879 13 8.4 × 10–5 Psmb4, Arpc2, Cyba, Atp6v1e1, Alox5, Ly96, Casp8, Gpi1, Pld4, Fbxw11, Cap1, Ifi204, Faf2 2.6 × 10
–7
COPI-mediated anterograde transport 94 4 0.012 Arcn1, Dync1i2, Capzb, Tmed7 1.1 × 10–4
TRIF-mediated programmed cell death 9 2 0.023 Ly96, Casp8 3.4 × 10–4
Cellular responses to external stimuli 382 6 0.024 Psmb4, Cyba, Nup153, Atg4c, Dync1i2, Capzb 4.4 × 10–4
G2/M Transition 169 4 0.035 Psmb4, Fbxw11, Dync1i2, Odf2 0.001
Neutrophil degranulation 476 6 0.035 Cyba, Alox5, Gpi1, Cap1, Ifi204, Faf2 0.001
CLEC7A (Dectin-1) signaling 84 3 0.035 Psmb4, Casp8, Fbxw11 0.001
Metabolism of proteins 1497 11 0.035 Psmb4, Nup153, Tnks2, Btbd1, Arcn1, Fbxw11, Dync1i2, Eif3d, Capzb, Mrps17, Tmed7 0.001
ROS, RNS production in phagocytes 32 2 0.047 Cyba, Atp6v1e1 0.003
Enriched pathways for ≥ 2-fold enhanced expression at 25 dpi versus baseline
Class I MHC–mediated antigen 
processing and presentation 344 6 0.006 Vamp3, Psmb10, Ube2r2, Asb13, Socs3, Ncf4 1.3 × 10
–4
Biosynthesis of E-series 18(S)-resolvins 4 2 0.006 Alox5, Hpgd 7.5 × 10–5
Metabolism of proteins 1497 13 0.006
Igfbp4, Csnk2b, Mrpl30, Nucb1, Gas6, Psmb10, 
Ube2r2, Asb13, Socs3, Dync1i2, Dap3, Copg1, 
Mrps17
2.2 × 10–5
Immune system 1523 13 0.006 Csnk2b, Alox5, Vamp3, Psmb10, Ube2r2, Asb13, Cnpy3, Socs3, Pld4, Dync1i2, Ncf4, Cap1, Myo5a 2.6 × 10
–5
Mitochondrial translation termination 81 3 0.024 Mrpl30, Dap3, Mrps17 0.001
Posttranslational protein 
phosphorylation 114 3 0.043 Igfbp4, Nucb1, Gas6 0.002
Enriched pathways for ≥ 2-fold reduced expression at 6 dpi versus baseline
G α (i) signaling events 338 6 0.010 Ccl4, Rho, Ttr, Cxcl2, Pcp2, Metap2
2.9 × 10–5 
Enriched pathways for ≥ 2-fold reduced expression at 25 dpi versus baseline
G α (i) signaling events 338 11 6.6 × 10–9 Rcvrn, Gnb3, Pde6g, Gngt1, Rho, Guca1a, Ttr, Sag, Opn1sw, Pcp2, Gng13 4.8 × 10
–11
β-Catenin–independent WNT signaling 116 6 6.8 × 10–6 Ap2m1, Gnb3, Pde6g, Gngt1, Psma3, Gng13 1.3 × 10–7
Activation of the phototransduction 
cascade 8 3 4.9 × 10
–5 Pde6g, Gngt1, Rho 1.1 × 10–6
The citric acid (TCA) cycle and respiratory 
electron transport 129 5 2.0 × 10
–4 Sdhb, Atp5j, Ndufb8, mt-Atp6, mt-Nd3 6.1 × 10–6
Metabolism 1685 12 2.0 × 10–4 Sdhb, Ptgds, Atp5j, Gnb3, Ndufb8, Gngt1, Ttr, mt-Atp6, mt-Nd3, Aldoa, Psma3, Gng13 6.6 × 10
–5
Opsins 8 2 0.001 Rho, Opn1sw 1.6 × 10–4
Synthesis, secretion, and inactivation of 
Glucagon-like Peptide-1 (GLP-1) 10 2 0.002 Gnb3, Gng13 2.4 × 10
–4
Cristae formation 17 2 0.004 Atp5j, mt-Atp6 6.2 × 10–4
GPCR ligand binding 371 5 0.004 Gnb3, Gngt1, Rho, Opn1sw, Gng13 7.9 × 10–4
Inhibition of voltage gated Ca2+ 
channels via Gβ/γ subunits 23 2 0.006 Gnb3, Gngt1 0.001
The canonical retinoid cycle in rods 
(twilight vision) 24 2 0.006 Rho, Ttr 0.001
Innate Immune System 879 7 0.007 Ctsb, Srp14, Ttr, Aldoa, B2m, Pld3, Psma3 0.002
Complex I biogenesis 52 2 0.020 Ndufb8, mt-Nd3 0.005
Antigen processing — cross presentation 80 2 0.041 B2m, Psma3 0.011
PCP/CE pathway 82 2 0.043 Ap2m1, Psma3 0.012
Enriched reactome pathways searched against genome with a 5% threshold for FDR.
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In this study, using longitudinal imaging and single-cell transcriptional profiling, we show that the ret-
inal innate immune response in EAE takes place in 2 distinct waves: the early microglial response before 
onset (6 dpi), which is associated with subsequent neuroaxonal damage and is characterized by a pathogen 
response profile, and a later response (25 dpi), which is characterized by a more neuroprotective profile. 
Through longitudinal monitoring of  the density of  a targeted population of  cells, our data suggest that these 
distinct effects are mediated via different populations. Understanding the dynamics of  injurious and protec-
tive microglial activation in EAE is a critical step to distinguishing and finally modulating microglial activity 
(i.e., enforcing protective and inhibiting harmful effects).
Prior important descriptive analysis of  retinal histopathology associated with in vivo OCT already 
inferred a possible direct effect of  microglia on neuroaxonal damage. In addition to evaluating other cell 
types, histopathological evidence showed an early increase of  microglia, and in separate animals in vivo, OCT 
showed later IRL thinning as a metric of  neuroaxonal injury (8). By combining concurrent OCT and CLSO, 
we were able to detail the dynamics of  microglial response. We confirmed an early increase in microglial 
numbers preceding the onset of  neuroaxonal damage and established an indirect association between the 
number of  innate immune cells at peak of  disease and later RGC loss. Thus, our data confirm that, even in 
a myelin-devoid area of  the CNS like the retina, early immune activation — particularly of  innate immune 
cells — help mediate the inflammatory response and have downstream injurious effects on neurons in EAE.
In the case of  white matter, research indicates that the transition from a proinflammatory to a proregen-
erative microglial population is necessary to initiate remyelination and repair (2, 35, 39). Our CSLO data 
show a reduced cell density, and soma area of  retinal microglia shown around 30 dpi suggests a necroptosis 
and repopulation of  microglia. These results, thereby, suggest that the switch from a proinflammatory to a 
proregenerative microglial population is not solely based on the interaction of  microglia with myelinated 
axons but that it is also present in unmyelinated areas such as the retina. Therefore, this phenotype switch is 
not specific to remyelination but likely affords a milieu that is directed generally toward repair.
The transcriptomic profile of microglia prior to onset of EAE (6 dpi) showed the increased expression of  
various genes involved in immune response underlining the involvement of microglia in the acute inflammato-
ry process. These results are in line with an inflammation-enhancing and phagocytic microglial phenotype pre-
ceding disease onset. At the peak of retinal inflammation (25 dpi), the upregulation of these genes was already 
reversed in parts; multiple genes involved in antiinflammatory response were upregulated and polarization was 
downregulated, pointing toward a protective microglial function in the later stage of disease (40). Nevertheless, 
the purpose of a proregenerative microglia in the absence of myelin warrants further investigations.
It should be noted that OCT is limited in rodents to the central retina and lacks cellular resolution of  
RGCs. Also, although the CSLO and histological measurements matched well, they are still not fully con-
gruent. Finally, our study lacked scRNA-seq analyses (a) at 15 dpi to show microglial changes at the peak 
of  clinical signs, (b) at 50 dpi to show a persistence of  the proregenerative microglial subsets, and (c) of  
optic nerve microglia. Future work could prove direct neurodegenerative effects and regenerative potential 
of  microglia by depleting microglia at different time points in EAE (41).
To conclude, our data suggest that microglia play an important role in both retinal neurodegeneration 
and regeneration during EAE and that a phenotype switch is associated with the beginning of  regeneration 
and repair. Further studies are necessary to understand the pathophysiology of  different microglial func-
tions during the EAE disease course and their potential value as therapeutic targets.
Methods
Experimental design
First, we monitored retinal changes during EAE through OCT (retinal thickness) and CSLO (density and 
morphology of  innate immune cells). We then compared the expression profiles of  retinal innate immune 
cells at different time points of  EAE through scRNA-seq (Figure 4).
In vivo retinal monitoring in EAE
Mice. For experiments involving in vivo retinal imaging, CX3CR1GFP/+–knock-in mice were fully back-
crossed into C57BL/6J. We confirmed the absence of  an RD8 mutation (associated with hereditary mac-
ular degeneration). In CX3CR1GFP/+–knock-in mice, microglia, macrophages, monocytes, and NK cells 
express GFP, which can be imaged through CSLO (14), without any immunologic alterations (15).
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Induction and clinical scoring of  MOG35-55 EAE. Seven female mice at 10 weeks of  age were immunized s.c. 
with 100 μg of  MOG35–55 peptide (Genemed Synthesis) in complete Freund’s adjuvant containing 400 μg 
Mycobacterium tuberculosis H37Ra (Difco Laboratories). Mice received 200 ng pertussis toxin (List Biological) 
by i.p. injection at the time of  and after immunization. We monitored clinical scores, as described before (42).
Anesthesia. For retinal imaging, mice were anesthetized by mask inhalation of isoflurane vaporized at con-
centrations of 1.5% (2 L/min), and their pupils were dilated with 1% tropicamide ophthalmic solution (Akorn).
OCT. On 8, 12, 16, 21, 31, 48, and 55 dpi, after CSLO scanning and without moving the mouse, we 
performed volume OCT scans of  the IRL (combination of  the RNFL and the ganglion cell plus the inner 
plexiform layers) as previously described (42, 43). Scans consisted of  25 B-scans (2-dimensional images) 
recorded in high-resolution mode and rasterized from 30 averaged A-scans (1-dimensional scans).
Reliability of  CSLO measurements. To assess how CSLO measurements relate with real tissue dimensions, 
we imaged the retinal vasculature around the optic nerve head of  several mice, measuring the distance between 
given branches or intersections. Following in vivo imaging, mice were sacrificed, and eyeballs extracted as pre-
viously described (42). Retinas were then stained with an anti-CD31 (also known as anti–PECAM-1, Abcam, 
catalog ab28364) antibody. This antibody labels the endothelial cell intercellular junctions, allowing for fluo-
rescence microscopy identification and measurement of  the same vascular structures that had been analyzed 
in vivo. Distances from the same eloquent vascular intersections were measured and compared between in 
vivo and ex vivo images (Figure 5). Eighty-four distances were measured and compared on CSLO and on 
the microscope (Nikon E600, Q Capture Pro 7). Comparison of  distances between vascular intersections on 
both in vivo CSLO and matched flat-mount images showed that, in our setting, 1 pixel on a CSLO image 
corresponds to 1.054 ± 0.099 μm under the fluorescence microscope. Thus, in vivo CSLO measurements are 
reliable for longitudinal analysis of  morphological changes in CX3CR1GFP/+ retinae. This is the first study to 
our knowledge employing CSLO for in vivo immune cell imaging in a MS mouse model validating CSLO 
as a feasible and reliable technique for the longitudinal analysis of  retinal immune cell dynamics in mice 
Figure 4. Experimental design. Timelines for experiment I (first row) and experiment II (second row) with color-coded triangles marking time points for 
MOG35–55, CFA, and pertussis toxin (PT) injection (red), PT injection (gray), CSLO imaging (green), OCT imaging (blue), quantification of retinal ganglion cells 
on flatmounts (yellow), and extraction of retina for FACS and scRNA-seq analyses (brown).
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expressing fluorescent proteins. Especially in combination with other advanced techniques such as OCT and 
objective functional measurements (44–46), CSLO empowers the afferent visual system in rodents as a com-
prehensive model to study the pathophysiology of  CNS inflammation (42).
Longitudinal retinal CSLO, including acquisition and analysis. We performed retinal CSLO imaging on 0, 5, 9, 
13, 17, 21, 25, 31, 34, 38, 42, 48, and 56 dpi. We used a modified dual-line confocal scanning laser ophthal-
moscope with a specialized filter set optimized for this experiment (Spectralis spectral domain–OCT, 488 nm 
pumped semiconductor laser diode; 500–550 nm bandpass filter to detect GFP). First, the beam was focused 
on the RNFL layer with the aid of  an infrared fundus image (Figure 6). Then, the filter was changed to detect 
GFP autofluorescence. We obtained images at 4 different focal planes through the IRLs, by adjusting the 
focus knob. Images were then processed, and the area of  interest (defined as a well-focused, 350-pixel area, 
adjacent to the optic nerve head, while avoiding the major vasculature) was selected for cell count and calcu-
lation of  the soma area of  each cell (Figure 7).
Histological analysis and immunofluorescence microscopy. At day 56 after immunization, mice were sacrificed. We 
obtained counts of RGC for each retina through in situ immunofluorescence microscopy of retinal whole-mount 
stained against Brn3a (1:200, Santa Cruz Biotechnology Inc., catalog sc-31984), as described previously (42).
Transcriptomic changes in retinal microglia during EAE
Mice and time points. Ten-week-old WT female C57BL6/J mice were immunized as described above. Retinal 
innate immune cells were isolated and pooled for single-cell transcriptomic analysis at 6 (n = 21) and 25 (n = 
19) dpi. In the 25 dpi group, only retinas from mice developing EAE signs (from a total of 25 immunized) were 
pooled for analysis. Age-matched, nonimmunized female mice (n = 20) were used as controls. To avoid any 
batch effects, all retinas (from control mice and from those immunized 6 and 25 days prior) were extracted, 
digested, and pooled for analysis on the same day.
Isolation of  retinal innate immune cells. Following carbon dioxide euthanasia, the retinae were immediately 
eviscerated and incubated in papain solution (Worthington Papain Dissociation System) for 90 minutes at 
37°C, with gentle pipette mixing every 5 minutes (47). The mixture was then filtered through a 35 μL cell 
strainer and centrifuged at 300g for 5 minutes at room temperature (RT). The cell pellet was then resuspended 
in a DNase/albumin-inhibitor solution (provided with the dissociation system) and carefully layered over an 
albumin-inhibitor solution for a discontinuous density gradient by centrifuging at 70g for 6 minutes at RT. 
Figure 5. Reliability of CSLO measurements. (A and B) Microscopy image from a retinal flat mount. (C and D) The same 
retina, imaged in vivo through CSLO centered on the optic nerve head, one day prior to eye extraction. The red lines on B 
and D show measurements of the same arterial branch in vitro (B) and in vivo (D).
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Cells were then resuspended in a buffer containing phosphate buffered saline (PBS; pH 7.2), 0.5% bovine 
serum albumin (BSA), and 2 mM EDTA (MACS BSA Stock solution [Miltenyi Biotec, 130-091-376] dilut-
ed in autoMACS Rinsing Solution [Miltenyi Biotec, 130-091-222]) at 4°C, incubated initially with an FcR 
Blocking Reagent, mouse (Miltenyi Biotec, 130-092-575; 15 minutes at 4°C) and subsequently with a PerCP/
Cy5-conjugated CD11b anti-mouse/human CD11b antibody (BioLegend, 101228) during 20 minutes at 4°C. 
After live/dead staining (Invitrogen LIVE/DEAD Fixable Aqua Dead Cell Stain Kit for 405 nm excitation, 
REF L34957), cells were suspended in the above-mentioned buffer, centrifuged at 70g (5 minutes at 4°C), 
resuspended in buffer and held on ice until sorting.
Cells were sorted using a BD FACS Aria ll with 488 nm laser (for PerCP-Cy5.5, side scatter [SSC], forward 
scatter [FSC]), FACSDiva v8.0 software, and selecting live single cells based on FSC width, SSC width, and live/
dead exclusion. On FSC/SSC plots, live cells were evaluated for PerCP/Cy5-CD11b (Supplemental Figure 2).
scRNA-seq
Next-generation sequencing libraries. Suspensions of  FACS-isolated retinal cells according to size and CD11b 
staining were then prepared for single-cell isolation and library preparation at the Gladstone Genomics Core 
facility following the 10x Genomics Cell Preparation Guideline and the instructions for Preparation of  Limited 
Samples (48). Next-generation sequencing (scRNA-seq) libraries were obtained for each time-point (6 and 25 
dpi, plus nonimmunized controls) using a Chromium Single Cell 3′ Library and Gel Bead Kit (10x Genomics, 
120267) and a ChromiumTM Single Cell A Chip Kit (10x Genomics, 1000009).
High-throughput single-cell transcriptomic analysis of  retinal innate immune cells. We aligned raw sequence reads 
and generated gene count matrices using Cell Ranger v2.1.0 (10x Genomics). We performed quality control, 
clustering, and differential gene expression analysis using Seurat v2.2. (49) We used a total of 10,850 genes across 
329 immune cells (total cell count, n = 789) for further clustering analysis. Most variable genes were identified 
using principal component analysis (PCA) and performed t-distributed stochastic neighbor embedding (t-SNE) 
with significant principal components for clustering and visualization. We identified 17 clusters and defined cell 
types for each cluster including neuronal, retinal, and immune cells based on marker genes. We confirmed each 
immune cell type by correlations with public data sets using SingleR software (50). We retrieved immune cell 
clusters (7 from a total of 17 clusters) and performed clustering analysis within each immune cell population.
Statistics
All statistical analyses were performed using R version 3.6.1 and Microsoft Excel (51). All results are reported 
as mean ± SD, if  not reported otherwise. P < 0.05 were considered significant. To test the reliability of  in vivo 
CSLO versus ex vivo microscopy measurements, we analyzed the variability (mean ± SEM) of  the pixel/
μm ratios. Cross-sectional and longitudinal within- and between-group analyses, as well as correlations of  
CSLO, OCT, and histology data, were performed applying mixed linear effect models with accounting for 
Figure 6. CSLO in CX3CR1GFP/+–knock-in mice. (A) Infrared fundus image, focused on the retinal nerve fiber layer above 
the optic disc. (B) CSLO imaging of autofluorescent retinal GFP+ cells, which in healthy conditions correspond to resting 
microglia, in CX3CR1GFP/+–knock-in mice.
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the subject as a random factor. Differentially expressed genes for each immune cell subcluster were identified 
using Wilcoxon test. Significant genes were selected with 5% of FDR threshold. A functional network and 
enriched pathways for microglia were generated using Cytoscape, including the apps STRING and STRING 
ENRICHMENT (18, 19). For each time point, transcripts with significantly changed expression (P < 0.05) 
were included in the functional network, and transcripts with a ≥ 2-fold higher or lower expression were 
selected for enrichment analyses and compared versus the complete mus musculus genome as background 
using the Reactome Pathways library with a 5% FDR-threshold.
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Figure 7. CSLO image processing for the morphological analysis of innate immune cells. The image preparation on ImageJ includes background subtrac-
tion (–50 px), contrast enhancement (saturated pixels 1%), and Z-stacking after image alignment. Then, a sample area of 350 px (red circle) in the vicinity 
of the optic nerve head is selected, and the number of cells are measured (somata areas are not shown).
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